<DOC>
	<DOCNO>NCT00029965</DOCNO>
	<brief_summary>This study evaluate child glycosphingolipid ( GSL ) storage disorder investigate brain change cause nervous system degeneration . No experimental treatment offer study ; participant receive standard medical care disease . The information study may help researcher develop new therapy disorder monitor effect treatment . Patients age Tay-Sachs disease , Sandhoff disease , GM1 gangliosidosis , type 2 Gaucher disease may eligible study . Participants admit NIH Clinical Center 4 5 day every 6 month clinical evaluation involve follow test procedure : - Medical history - Physical , neurologic , eye examination - Developmental evaluation physical therapist , nutritionist psychologist - Blood test check nutritional status , liver kidney function , , patient treat seizure , level anti-seizure drug . Some blood also use research purpose . - Urinalysis check urine sugar level kidney function - Skin biopsy obtain cell grow culture . The biopsy area numb anesthetic cream 1/8-inch piece skin remove circular punch scissors . - Genetic analysis DNA screen mutation responsible patient GSL storage disorder - Magnetic resonance imaging ( MRI ) brain scan . Children type 2 Gaucher disease , Sandhoff disease GM1 gangliosidosis also liver spleen scan . Brain scan do every 6 month first year . After , may do less often , depend result . For MRI , child lie still narrow cylinder ( scanner ) . A magnetic field radio wave use produce picture organs study . ( Children sedate MRI . Children sedate test . ) - Electroencephalogram ( EEG ) measure electrical activity brain detect possible seizure . For test , electrode ( small metal disc attach wire ) attach child head paste brain wave ( electrical activity ) record child rest quietly . - Brainstem auditory evoke response ( BAER ) measure hear . Electrodes attach child head ( similar EEG procedure ) brain wave record sound stimulation give . - Lumbar puncture ( spinal tap ) study proteins cerebrospinal fluid , bathe brain spinal cord . A needle inserted space bone ( vertebra ) low back . About 2 tablespoon fluid collect needle . This test do anesthetic time MRI do . If child sedate , local anesthetic use .</brief_summary>
	<brief_title>Nervous System Degeneration Glycosphingolipid Storage Disorders</brief_title>
	<detailed_description>The GM1 GM2 gangliosidoses lysosomal storage disorder primarily affect brain uniformly fatal . No effective therapy patient diseases yet demonstrate . Historically , since disorder fatal little natural history information disease characterization use modern medical technique collect . This information vital order establish pattern disease progression identify clinical , biochemical biophysical marker use endpoint future therapeutic trial . This protocol aim study natural history GM1 GM2 gangliosidoses affect individual age , race gender use medical technology include MRI/MRS , hear evaluation auditory evoke response testing , EEG , well subspecialty evaluation rehabilitative medicine , ophthalmology , speech language pathology , neurology , psychology . Biomarkers disease progression explore CSF blood sample correlation disease stag . Fibroblast culture establish test potential therapeutic agent . We hypothesize relevant biomarkers correlate disease progression shed light pathophysiology disease progression devastate disorder . As mean acquire additional information , subject parent also ask complete questionnaire regard medical developmental history , initial clinical presentation disease step toward diagnosis . At request , questionnaire send family wish undergo clinical evaluation NIH , unstable travel , whose child already decease .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Gangliosidoses</mesh_term>
	<criteria>INCLUSION CRITERIA : Individuals great 6 month age GM1 GM2 gangliosidosis document enzyme deficiency and/or mutation analysis CLIAapproved laboratory EXCLUSION CRITERIA : Individuals opinion principal investigator medically fragile travel safely NIH evaluation Individuals unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 8, 2017</verification_date>
	<keyword>Tay-Sachs</keyword>
	<keyword>Lysosomal Storage Disease</keyword>
	<keyword>Sandhoff</keyword>
	<keyword>GM1 Gangliosidosis</keyword>
	<keyword>GM2 Gangliosidosis</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
	<keyword>Gaucher</keyword>
</DOC>